GEP-NETs
GEP-NETs
Advertisement
Katy MarshallGEP-NETs | February 22, 2024
For patients with NETs, somatostatin receptors are often targeted for nuclear theranostics applications.
Read More
Katy MarshallGEP-NETs | February 8, 2024
Investigators compared the benefits of a nomogram with the AJCC staging system in predicting overall survival.
Emily MenendezASCO GI 2024 | January 23, 2024
NETTER-2 is the first randomized study to demonstrate the efficacy of RLT as a 1L treatment for any form of cancer.
Katy MarshallGEP-NETs | December 19, 2023
Physicians currently have a limited understanding of how to properly diagnose and treat type 1 gastric NETs.
Katy MarshallGEP-NETs | November 3, 2023
Researchers analyzed cabozantinib's ability to improve the progression-free survival rate for patients.
Patrick DalyGEP-NETs | September 11, 2023
A study found key tumor heterogeneities, including Ki-67 indices, might contribute to disease progression in GEP-NETs.
Patrick DalyGEP-NETs | September 11, 2023
Lu-177-dotatate in PRRT appeared to treat GEP-NETs, though prior internal radiation may impede responses or worsen survival.
Rob DillardGI Cancer | August 24, 2023
Researchers identified a circRNA signature as a potential biomarker for GEP-NETs.
Rob DillardGI Cancer | August 24, 2023
Patients with advanced stage gastroenteropancreatic neuroendocrine tumors appear to benefit from PRRT.
Kerri FitzgeraldSNMMI | August 24, 2023
The authors of the study won the 2022 SNMMI Abstract of the Year Award.
Advertisement
Advertisement
Advertisement
Latest News

February 28, 2024